Compare MNKD & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNKD | PFLT |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.6M | 805.6M |
| IPO Year | 2004 | 2010 |
| Metric | MNKD | PFLT |
|---|---|---|
| Price | $2.72 | $8.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $8.56 | ★ $10.67 |
| AVG Volume (30 Days) | ★ 4.5M | 982.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 14.12% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $348,966,000.00 | N/A |
| Revenue This Year | $35.81 | $8.16 |
| Revenue Next Year | $11.89 | N/A |
| P/E Ratio | $138.50 | ★ $24.14 |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $7.68 |
| 52 Week High | $6.51 | $10.88 |
| Indicator | MNKD | PFLT |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 63.20 |
| Support Level | $2.52 | $8.40 |
| Resistance Level | $4.09 | $9.46 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.11 | 0.08 |
| Stochastic Oscillator | 88.99 | 94.86 |
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.